FDA approves first herbal medicine for clinical trial on COVID-19 treatment
The trials will be conducted at two sites, the FDA has said
Jonas Danquah 
Ghana's Food and Drugs Authority (FDA) has approved a herbal medicine known as Cryptolepis sanguinolenta locally known as Nibima, for clinical trials, in search of treatment for the coronavirus disease (COVID-19).
A statement issued by the Authority noted that the trials will be conducted at two sites.
The statement disclosed that the herbal medicine was submitted by the “School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST)" in September 2020.
READ ALSO:
5 nurses die of coronavirus, over 800 infected - GRNMA
According to the Authority, the approval was granted in January 2021.
“The Food and Drugs Authority (FDA), The National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021.”
The Authority added that it gave the authorization after “detailed assessment.”
Read full statement below
